Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody

60Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Obinutuzumab (GA101) is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the FcγRIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. Preclinical data demonstrated more efficient B-cell depletion in whole blood and superior antitumor activity in xenograft models of obinutuzumab as compared to the type I CD20 antibody rituximab. In previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, obinutuzumab plus chlorambucil increased response rates and prolonged progression-free survival compared with rituximab plus chlorambucil. Obinutuzumab had an acceptable and manageable safety profile, with infusion-related reactions during the first infusion as the most common adverse event. Further phase I/II clinical trials have also shown promising activity in other CD20-positive B-cell non-Hodgkin's lymphomas (NHL). Therefore, several clinical studies are planned or ongoing to investigate obinutuzumab with different combination partners in both untreated and relapsed/refractory patients with different B-cell NHL entities, which in addition to CLL include diffuse large B-cell lymphoma and follicular lymphoma.

Cite

CITATION STYLE

APA

Goede, V., Klein, C., & Stilgenbauer, S. (2015, April 1). Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin’s Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncology Research and Treatment. S. Karger AG. https://doi.org/10.1159/000381524

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free